LIVIVO - Search results -

Search results

Result 1 - 10 of total 305

Search options

Article: Primary hyperoxaluria type 1: time for prime time?

Bacchetta, Justine / Wood, Kyle D

2022 Volume 15, Issue Suppl 1, Page(s) i1–i3

Abstract: Oxalate crystals in the kidney were first described in 1925. Since then, many major milestones have been reached in the understanding of genetic primary hyperoxaluria(s). Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disease due to a ... ...

Abstract	Oxalate crystals in the kidney were first described in 1925. Since then, many major milestones have been reached in the understanding of genetic primary hyperoxaluria(s). Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disease due to a mutation in the
Language	English
Publishing date	2022-05-17
Publishing country	England
Document type	Editorial
ZDB-ID	2655800-2
ISSN	2048-8513 ; 2048-8505
ISSN (online)	2048-8513
ISSN	2048-8505
DOI	10.1093/ckj/sfab233
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6587: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence.

Lyall, Vikram S / Wood, Kyle D / Pais, Vernon M

The New England journal of medicine

2023 Volume 388, Issue 21, Page(s) 2014

MeSH term(s)	Humans ; Hydrochlorothiazide/therapeutic use ; Kidney Calculi ; Kidney
Chemical Substances	Hydrochlorothiazide (0J48LPH2TH)
Language	English
Publishing date	2023-05-24
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	207154-x
ISSN	1533-4406 ; 0028-4793
ISSN (online)	1533-4406
ISSN	0028-4793
DOI	10.1056/NEJMc2304100
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.34: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: How We Treat Primary Hyperoxaluria Type 1.

Breeggemann, Matthew C / Harris, Peter C / Lieske, John C / Tasian, Gregory E / Wood, Kyle D

Clinical journal of the American Society of Nephrology : CJASN

2024

Language	English
Publishing date	2024-03-18
Publishing country	United States
Document type	Journal Article
ZDB-ID	2226665-3
ISSN	1555-905X ; 1555-9041
ISSN (online)	1555-905X
ISSN	1555-9041
DOI	10.2215/CJN.0000000000000460
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6584: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Saving the planet with reduced routine DMARD blood monitoring frequency.

Wood, Natasha A E / Farmer, Leila / Croker, Richard / Kyle, Stuart / Lewis, Tom

BMJ (Clinical research ed.)

2023 Volume 382, Page(s) 1645

MeSH term(s)	Humans ; Antirheumatic Agents/therapeutic use ; Planets ; Arthritis, Rheumatoid/drug therapy ; Severity of Illness Index
Chemical Substances	Antirheumatic Agents
Language	English
Publishing date	2023-07-18
Publishing country	England
Document type	Letter ; Comment
ZDB-ID	1362901-3
ISSN	1756-1833 ; 0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
ISSN (online)	1756-1833
ISSN	0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
DOI	10.1136/bmj.p1645
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The Effects of Previous Experiences of Healthcare Discrimination on HIV Intervention Outcomes.

Chang, Kyle / D'Anna, Laura Hoyt / Owens, Jaelen / Wood, Jefferson

AIDS and behavior

2024

Abstract: Although several healthcare interventions have been developed to address HIV among young Black/African American men who have sex with men (YBMSM), the HIV epidemic in the United States continues to disproportionately burden this population. The current ... ...

Abstract	Although several healthcare interventions have been developed to address HIV among young Black/African American men who have sex with men (YBMSM), the HIV epidemic in the United States continues to disproportionately burden this population. The current study examines previous healthcare discrimination and how it affects HIV intervention delivery. One hundred seventy-two YBMSM participated in the Peer Promotion of Wellness and Enhanced Linkage to Resources (PPOWER) project, which used a short, multi-faceted, community-level intervention based on Community Peers Reaching Out and Modeling Intervention Strategies (Community PROMISE). Data were collected at baseline, a 45-day follow up, and a 90-day follow up. Generalized Estimating Equations (GEE) were used to examine the effects of previous healthcare discrimination on outcomes related to HIV testing, alcohol and drug use, and sexual behaviors. Previous healthcare discrimination was found to moderate the relationship between time and intentions to test for HIV, perceptions of sexual risk, problem marijuana use, and problem other drug use, such that those who had experienced more healthcare discrimination showed greater improvements over time compared to those who had experienced less healthcare discrimination. The results of the current study suggest that a community-level peer intervention, in combination with a component to promote cultural competency and address prior experiences of discrimination in healthcare settings, may be highly effective for people who have experienced a barrier in their continuum of care as a result of racial discrimination.
Language	English
Publishing date	2024-02-17
Publishing country	United States
Document type	Journal Article
ZDB-ID	1339885-4
ISSN	1573-3254 ; 1090-7165
ISSN (online)	1573-3254
ISSN	1090-7165
DOI	10.1007/s10461-024-04267-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6451: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Laparoscopic-Assisted Transvaginal Cholecystectomy - the US Military Experience With Long-Term Follow Up.

Judge, Carolyn / Bandle, Jesse / Wang, Andrew / Gadbois, Kyle / Simsiman, Amanda / Wood, Robin / Wisbach, Gordon

JSLS : Journal of the Society of Laparoendoscopic Surgeons

2024 Volume 28, Issue 1

Abstract: Objectives: We present our initial clinical experience applying Natural Orifice Transluminal Endoscopic Surgical (NOTES) technique to perform cholecystectomy in ten patients at a military institution.: Methods: A posterior colpotomy was created to ... ...

Abstract	Objectives: We present our initial clinical experience applying Natural Orifice Transluminal Endoscopic Surgical (NOTES) technique to perform cholecystectomy in ten patients at a military institution. Methods: A posterior colpotomy was created to accommodate a single site working port used to facilitate dissection and gallbladder mobilization under direct visualization via an infraumbilical port. The specimen was retrieved through the vagina and the colpotomy was closed with absorbable suture under direct visualization. Long-term follow up was performed over the phone to assess quality of life with 2 widely used health-related quality of life (HRQoL) surveys including RAND-36 Health Item Survey (Version 1.0), Results: Ten women underwent a laparoscopic-assisted transvaginal cholecystectomy (TVC) with 7 available for long-term follow-up. The average age was 28.9 years (20-37) and the indications for surgery included symptomatic cholelithiasis (9) and biliary dyskinesia (1). The mean operative time was 129 mins (95-180), and median blood loss was 34 ml (5-400). There were no conversions and the average length of stay was 9.98 hours (2.4-28.8). Pain (analogue scale 1-10) on postoperative day three was minimal (mean 2.3) and was limited to the infraumbilical incision. On average patients returned to work by postoperative day six and resumed normal daily activities at seven days. Immediate postoperative complications included one incident of postoperative urinary retention requiring bladder catheterization. One intra-operative cholangiogram was successfully performed due to elevated preoperative liver enzymes without significant findings. Long-term complications included one asymptomatic incisional hernia repair at the infraumbilical port site. The RAND-36 survey demonstrated an average physical and mental health summary score of 82.2 and 63.7 with an average general health score of 63.6. The average FSFI total score was 21.8. Conclusion: TVC is safe and effective. Implementation may improve operational readiness by returning service members to normal activities more expeditiously than conventional laparoscopy.
MeSH term(s)	Female ; Humans ; Adult ; Quality of Life ; Follow-Up Studies ; Military Personnel ; Cholecystectomy/methods ; Laparoscopy/methods ; Vagina/surgery ; Natural Orifice Endoscopic Surgery/methods ; Postoperative Complications/surgery
Language	English
Publishing date	2024-03-18
Publishing country	United States
Document type	Case Reports
ZDB-ID	2011211-7
ISSN	1938-3797 ; 1086-8089
ISSN (online)	1938-3797
ISSN	1086-8089
DOI	10.4293/JSLS.2023.00059
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5183: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 310: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Endogenous Oxalate Synthesis and Urinary Oxalate Excretion.

Fargue, Sonia / Wood, Kyle D / Crivelli, Joseph J / Assimos, Dean G / Oster, Robert A / Knight, John

Journal of the American Society of Nephrology : JASN

2023 Volume 34, Issue 9, Page(s) 1505–1507

MeSH term(s)	Oxalates/urine ; Humans
Chemical Substances	Oxalates
Language	English
Publishing date	2023-06-14
Publishing country	United States
Document type	Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	1085942-1
ISSN	1533-3450 ; 1046-6673
ISSN (online)	1533-3450
ISSN	1046-6673
DOI	10.1681/ASN.0000000000000176
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3344: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Progress with RNA Interference for the Treatment of Primary Hyperoxaluria.

Sawyer, Kathryn / Leahy, Stephen / Wood, Kyle D

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

2022 Volume 36, Issue 4, Page(s) 437–441

Abstract: Over the last few years, US Food and Drug Administration-approved drugs using RNA interference have come to the market. Many have treated liver-specific diseases utilizing N-acetyl galactosamine conjugation because of its effective delivery and limited ... ...

Abstract	Over the last few years, US Food and Drug Administration-approved drugs using RNA interference have come to the market. Many have treated liver-specific diseases utilizing N-acetyl galactosamine conjugation because of its effective delivery and limited off-target effects. The autosomal recessive disorder primary hyperoxaluria, specifically type 1, has benefited from these developments. Primary hyperoxaluria arises from mutations in the enzymes involved in endogenous oxalate synthesis. The severity of disease varies but can result in kidney failure and systemic oxalosis. Until recently, the treatment options were limited and focused primarily on supportive treatments, pyridoxine use in a subset of patients with primary hyperoxaluria type 1, and liver-kidney transplants in those who progressed to kidney failure. Two genes have been targeted with RNA interference; lumasiran targets glycolate oxidase and nedosiran targets lactate dehydrogenase A. Lumasiran was recently approved in the treatment of primary hyperoxaluria type 1 and nedosiran is in the approval process. Unfortunately, despite initial hopes that nedosiran may also be a treatment option for primary hyperoxaluria types 2 and 3, initial data suggest otherwise. The use of RNA interference liver-specific targeting for the treatment of primary hyperoxaluria type 1 will likely transform the natural history of the disease.
MeSH term(s)	Humans ; Hyperoxaluria, Primary/genetics ; Hyperoxaluria, Primary/therapy ; RNA Interference ; RNA, Small Interfering ; Renal Insufficiency/genetics ; United States
Chemical Substances	RNA, Small Interfering ; lumasiran (RZT8C352O1)
Language	English
Publishing date	2022-06-22
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	1364202-9
ISSN	1179-190X ; 1173-8804
ISSN (online)	1179-190X
ISSN	1173-8804
DOI	10.1007/s40259-022-00539-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4112: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Is It Time to Retire the Low-Oxalate Diet? No!

Crivelli, Joseph J / Wood, Kyle D / Assimos, Dean G

Journal of endourology

2021 Volume 35, Issue 10, Page(s) 1435–1437

MeSH term(s)	Calcium Oxalate ; Diet ; Humans ; Oxalates
Chemical Substances	Oxalates ; Calcium Oxalate (2612HC57YE)
Language	English
Publishing date	2021-08-18
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	356931-7
ISSN	1557-900X ; 0892-7790
ISSN (online)	1557-900X
ISSN	0892-7790
DOI	10.1089/end.2021.0576
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2628: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 208: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.

Piscitelli, Joseph / Reddy, Micaela B / Wollenberg, Lance / Del Frari, Laurence / Gong, Jason / Wood, Linda / Zhang, Yizhong / Matschke, Kyle / Williams, Jason H

Clinical pharmacokinetics

2024 Volume 63, Issue 4, Page(s) 483–496

Abstract: Background and objectives: Encorafenib is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma or metastatic colorectal cancer, respectively, with selected BRAF V600 mutations. A clinical drug-drug ... ...

Abstract	Background and objectives: Encorafenib is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma or metastatic colorectal cancer, respectively, with selected BRAF V600 mutations. A clinical drug-drug interaction (DDI) study was designed to evaluate the effect of encorafenib on rosuvastatin, a sensitive substrate of OATP1B1/3 and breast cancer resistance protein (BCRP), and bupropion, a sensitive CYP2B6 substrate. Coproporphyrin I (CP-I), an endogenous substrate for OATP1B1, was measured in a separate study to deconvolute the mechanism of transporter DDI. Methods: DDI study participants received a single oral dose of rosuvastatin (10 mg) and bupropion (75 mg) on days - 7, 1, and 14 and continuous doses of encorafenib (450 mg QD) and binimetinib (45 mg BID) starting on day 1. The CP-I data were collected from participants in a phase 3 study who received encorafenib (300 mg QD) and cetuximab (400 mg/m Results: Bupropion exposure was not increased, whereas rosuvastatin C Conclusion: The results from these clinical studies suggest that encorafenib does not cause clinically relevant CYP2B6 induction or inhibition but is an inhibitor of BCRP and may also inhibit OATP1B1/3 to a lesser extent. Based on these results, it may be necessary to consider switching statins or reducing statin dosage accordingly for coadministration with encorafenib. Clinical trial registration: ClinicalTrials.gov NCT03864042, registered 6 March 2019.
MeSH term(s)	Humans ; Rosuvastatin Calcium/pharmacokinetics ; Rosuvastatin Calcium/administration & dosage ; Male ; Drug Interactions ; Female ; Middle Aged ; Adult ; Sulfonamides/administration & dosage ; Sulfonamides/pharmacokinetics ; Sulfonamides/pharmacology ; Carbamates/administration & dosage ; Carbamates/pharmacokinetics ; Bupropion/administration & dosage ; Bupropion/pharmacokinetics ; Coproporphyrins ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage ; Liver-Specific Organic Anion Transporter 1/antagonists & inhibitors ; Liver-Specific Organic Anion Transporter 1/genetics ; Liver-Specific Organic Anion Transporter 1/metabolism ; Aged ; ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism ; ATP Binding Cassette Transporter, Subfamily G, Member 2/genetics ; Young Adult
Chemical Substances	Rosuvastatin Calcium (83MVU38M7Q) ; encorafenib (8L7891MRB6) ; Sulfonamides ; Carbamates ; Bupropion (01ZG3TPX31) ; Coproporphyrins ; coproporphyrin I (531-14-6) ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Liver-Specific Organic Anion Transporter 1 ; SLCO1B1 protein, human ; ATP Binding Cassette Transporter, Subfamily G, Member 2
Language	English
Publishing date	2024-02-29
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	197627-8
ISSN	1179-1926 ; 0312-5963
ISSN (online)	1179-1926
ISSN	0312-5963
DOI	10.1007/s40262-024-01352-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1246: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito